UNSPSC 51432112: Guanfacine hydrochloride

This classification denotes an antihypertensive agent and alpha-adrenergic agonist with the molecular formula C9H9Cl2N3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PML56A160O, chemically known as n-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide but more generally known as guanfacine hydrochloride, which bears US NIH Compound Identifier 3519. European Medicines Agency schedules Guanfacine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02427MIG.

UNSPSC 51432112 Guanfacine hydrochloride is a Commodity code that represents a single active pharmaceutical ingredient procured by state and local health agencies, fire departments, and pharmacy benefit programs. State and local governments purchase guanfacine hydrochloride primarily through emergency medical services procurement, state pharmacy benefit programs, and multistate cooperative purchasing consortia that aggregate demand for generic and branded pharmaceuticals. The work involves sourcing, warehousing, and distributing pharmaceutical products that meet FDA compliance, cGMP certification, and Drug Supply Chain Security Act requirements, with vendors responsible for maintaining expiration-date standards, providing Safety Data Sheets compliant with OSHA Hazard Communication Standards, and arranging logistics through authorized pharmaceutical wholesalers.

Issuing bodies include city fire and rescue departments (Tampa Fire Rescue), state health and human services commissions (Texas HHS), and multistate cooperative purchasing organizations (Minnesota MMCAP). Recent activity spans Florida, Texas, and Minnesota–Oregon regions. Representative recent opportunities include a Tampa Fire Rescue advanced life support medications procurement (IFB 26P00188, due April 8, 2026, estimated contract value $40,000.00) soliciting multiple medication line items including Labetalol, Epinephrine, Adenosine, and Diltiazem for emergency medical use; the Texas HHS Commission's Request for Information on direct-to-manufacturer prescription programs (RFI HHS0017013, posted April 3, 2026) exploring vendor capacity for self-insured pharmacy benefit contracting outside traditional PBM and wholesaler channels; and the Minnesota MMCAP multistate RFP for generic multi-source pharmaceuticals (S1070000015802, due March 26, 2026, with awards effective July 1, 2026) requiring submission of detailed NDC codes, pricing in multiple formats, and contractual relationships with AmerisourceBergen, Cardinal Health, or Morris & Dickson. Tampa's procurement carried a Small Local Business Enterprise set-aside with a 5 percent bid discount capped at $10,000. The MMCAP RFP allocated contract weight 75 percent to price competitiveness and required $5 million commercial general liability coverage plus network security and professional liability insurance.